In recent years, the pharmaceutical industry has been quietly transforming under the influence of geopolitical pressures, evolving trade policies, and rising costs of conducting trials in traditional markets. These factors are prompting sponsors to rethink their market-entry strategies, with Europe emerging as a key region for clinical development.
While the United States remains central to early-stage research and innovation, many organizations are increasingly recognizing the strategic benefits of expanding development and launch activities in Europe. A robust regulatory framework, coordinated regional initiatives, and targeted efforts under the EU Strategic Agenda 2024–2029 to enhance clinical trial competitiveness are making Europe an increasingly attractive environment for clinical research.
In this evolving landscape, logistics has moved from being an operational afterthought to a critical strategic function. Early decisions about where and how to position infrastructure can determine whether a program navigates the EU regulatory environment efficiently or faces costly delays. For advanced therapies, such as cell and gene treatments (CGTx), even minor logistical missteps can jeopardize product viability, underscoring the vital role of integrated, strategic planning in clinical development.
